Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ARGS is in the long-term down -100% below S&P in 3 years.
Description: Argos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases. The company develops immunotherapies based on Arcelis, its proprietary technology platform. Its products include AGS-003, which is under Phase III clinical trials and intended for the treatment of metastatic renal cell carcinoma (clear cell); and AGS-004, which is under Phase IIb clinical trials and is intended for the treatment of Human Immunodeficiency Virus. The company also develops AGS-003 for metastatic renal cell carcinoma (non-clear cell), early stage RCC, and other solid tumors. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is headquartered in Durham, North Carolina.
|Shares Outstanding||EPS||-1.1||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-62.16%||Sales Growth - Q/Q||-40.92%||P/E||-0.35|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-114.18%||ROE||-408.31%||ROI|
|Current Ratio||7.22||Quick Ratio||Long Term Debt/Equity||0.74||Debt Ratio||0.38|
|Gross Margin||Operating Margin||-4392.69%||Net Profit Margin||-4494.17%||Dividend Payout Ratio|
|Cash From Financing Activities||180 K||Cash From Investing Activities||6.21 M||Cash From Operating Activities||-14.57 M||Gross Profit|
|Net Profit||-17.55 M||Operating Profit||-16.96 M||Total Assets||53.29 M||Total Current Assets||40.39 M|
|Total Current Liabilities||5.6 M||Total Debt||29.75 M||Total Liabilities||38.39 M||Total Revenue||180 K|
|High 52 week||3.46||Low 52 week||0.02||Last close||0.06||Last change||-14.29%|
|RSI||71.58||Average true range||0.02||Beta||0.93||Volume||148.63 K|
|Simple moving average 20 days||23.52%||Simple moving average 50 days||-29.43%||Simple moving average 200 days||-67.27%|
|Performance Week||-14.29%||Performance Month||-3.23%||Performance Quart||-70.73%||Performance Half||-61.32%|
|Performance Year||-97.86%||Performance Year-to-date||100%||Volatility daily||27.39%||Volatility weekly||61.24%|
|Volatility monthly||125.5%||Volatility yearly||434.75%||Relative Volume||414.79%||Average Volume||55.82 K|
|New High||New Low|
2018-08-31 08:25:00 | New Research Coverage Highlights Argos Therapeutics, Triumph Group, Rigel Pharmaceuticals, Egalet, Hertz Global, and ACADIA Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018
2018-05-16 07:05:00 | Free Stock Performance Review on Array BioPharma and Three More Biotech Industry
2018-04-27 08:30:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Bottomline Technologies, SkyWest, Pacific Biosciences of California, Argos Therapeutics, Luminex, and Fiserv — New Research Emphasizes Economic Growth
2018-04-19 12:43:15 | Argos discontinues troubled trial, delists from Nasdaq
2018-04-19 12:31:15 | Here’s What’s Dragging Argos Therapeutics ARGS Stock Down Today
2018-04-13 07:20:00 | Blog Exposure - Alexion Pharma to Acquire Swedish Biotech Wilson Therapeutics
2018-04-02 08:50:37 | Argos Therapeutics reports 4Q loss
2018-03-01 08:15:00 | Detailed Research: Economic Perspectives on Navigant Consulting, CalAmp, Sonoco Products, Argos Therapeutics, K2M Group, and Altra Industrial Motion — What Drives Growth in Today's Competitive Landscape
2018-02-12 17:09:37 | A Daytrader's Guide To Fear
2018-02-05 16:47:16 | Argos Obtains Option to License PD1 Checkpoint Inhibitors
2018-01-22 17:55:11 | Heat latest Triangle biopharma to execute reverse stock split
2018-01-19 14:15:08 | Argos executes reverse stock split
2018-01-18 08:00:00 | Argos Announces One-for-Twenty Reverse Stock Split
2018-01-08 08:30:00 | Argos Announces $1.5 Million Equity Investment by Lummy Hong Kong, Ltd.
2018-01-04 08:10:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Sonoco Products, Argos Therapeutics, CDW, Cenveo, CoBiz Financial, and Oppenheimer — New Research Emphasizes Economic Growth
2017-12-29 12:25:09 | Should You Worry About Argos Therapeutics Inc’s NASDAQ:ARGS CEO Pay?
2017-12-22 11:32:10 | ETFs with exposure to Argos Therapeutics, Inc. : December 22, 2017
2017-12-14 11:15:10 | One Thing To Consider Before Buying Argos Therapeutics Inc NASDAQ:ARGS
2017-12-11 13:29:57 | ETFs with exposure to Argos Therapeutics, Inc. : December 11, 2017
2017-11-30 13:23:50 | ETFs with exposure to Argos Therapeutics, Inc. : November 30, 2017
2017-11-28 08:00:00 | Argos Provides Financial Update
2017-11-13 10:19:42 | Edited Transcript of ARGS earnings conference call or presentation 13-Nov-17 1:30pm GMT
2017-11-13 06:15:00 | Argos Therapeutics, Inc. to Host Earnings Call
2017-11-10 05:01:40 | Argos Therapeutics reports 3Q loss
2017-11-09 16:46:32 | Argos Reports Third Quarter 2017 Financial Results and Operational Highlights
2017-11-09 12:05:00 | Argos Therapeutics, Inc. to Host Earnings Call
2017-11-06 16:30:00 | Argos Announces Receipt of Milestone Payment from Lummy Hong Kong Co. Ltd.
2017-11-06 11:05:51 | ETFs with exposure to Argos Therapeutics, Inc. : November 6, 2017
2017-11-01 21:01:30 | Who Are The Major Shareholders Of Argos Therapeutics Inc ARGS?
2017-10-25 09:49:52 | ETFs with exposure to Argos Therapeutics, Inc. : October 25, 2017
2017-10-18 20:11:31 | NasdaqGM Healthcare Industry: A Deep Dive Into Argos Therapeutics Inc ARGS
2017-10-11 11:11:18 | ETFs with exposure to Argos Therapeutics, Inc. : October 11, 2017
2017-09-26 16:30:00 | Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors
2017-09-26 10:41:07 | ETFs with exposure to Argos Therapeutics, Inc. : September 26, 2017
2017-09-18 10:49:10 | Argos Therapeutics Inc ARGS: What Does It Mean For Your Portfolio?
2017-09-11 20:50:25 | ETFs with exposure to Argos Therapeutics, Inc. : September 12, 2017